D. Boral Capital began coverage on shares of Coya Therapeutics (NASDAQ:COYA – Get Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $15.00 price target on the stock. D. Boral Capital’s price target would suggest a potential upside of 150.84% from the stock’s previous close.
A number of other research analysts also recently commented on COYA. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th.
Check Out Our Latest Report on COYA
Coya Therapeutics Price Performance
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. As a group, equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.
Insiders Place Their Bets
In related news, CEO Arun Swaminathan bought 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at $36,700. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 9,510 shares of company stock valued at $69,615 over the last 90 days. 12.00% of the stock is owned by company insiders.
Institutional Investors Weigh In On Coya Therapeutics
A number of hedge funds have recently added to or reduced their stakes in COYA. Vanguard Group Inc. raised its stake in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in Coya Therapeutics in the third quarter worth about $169,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the second quarter worth about $101,000. Gilbert & Cook Inc. bought a new stake in Coya Therapeutics in the second quarter worth about $61,000. Finally, Geode Capital Management LLC raised its position in Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.
About Coya Therapeutics
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
- Five stocks we like better than Coya Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- How Can Investors Benefit From After-Hours Trading
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- How to Choose Top Rated Stocks
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.